Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs . Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults .
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.
• Treatment of symptomatic gastroesophageal reflux disease (GERD) in
patients 1 year of age and older
• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in
patients 1 month of age and older
• Maintenance of healing of EE due to acid-mediated GERD in patients 1
year of age and older
• Pathologic hypersecretory conditions in adults
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole
- Conditions
- Interventions
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Vivoryon Therapeutics N.V.
- Target Recruit Count
- 18
- Registration Number
- NCT02190708
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT02182336
Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2014-05-16
- Target Recruit Count
- 60
- Registration Number
- NCT02140073
- Locations
- 🇧🇾
Mother and Child National Reaserch Centre, Minsk, Belarus
🇧🇾Gastroenterology and Nutrition Department. Byelorussian Medical Academy Postgraduate Education, Minsk, Belarus
The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2016-09-26
- Lead Sponsor
- Loma Linda University
- Registration Number
- NCT02123498
- Locations
- 🇺🇸
1895 Orange Tree Lane, Suite 102, Redlands, California, United States
🇺🇸11234 Anderson Street, Loma Linda, California, United States
Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Target Recruit Count
- 45
- Registration Number
- NCT02085018
- Locations
- 🇬🇧
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne & Wear, United Kingdom
"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 150
- Registration Number
- NCT02028234
- Locations
- 🇮🇹
Sapienza Univeristy of Rome, Rome, Italy
A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT02013453
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 82
- Registration Number
- NCT02013427
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
A Study of Baricitinib and Omeprazole in Healthy Participants
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01925144
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
Prilosec Bioequivalence Study in Healthy Volunteers
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT01921920
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.